News

We’re very pleased to announce the expansion of our lab’s analytical capabilities. By adding two new lab devices, we’ve enabled deeper assessments of many important parameters for clinical studies, especially biomarker identification and measurement.

The fully automated and highly versatile Alegria^® from Orgentec allows the measurement of over 100 parameters, including some that are important in the assessment of a patient’s eligibility for a clinical study. Among the devices capabilities are autoimmune serology screening (e.g., ANCA, anti-insulin antibody and anti-CCP antibody assessment), infectious disease monitoring (e.g., anti-EBV antibody screening), and stool diagnostics (e.g., calprotectin measurements).

Our other new instrument is the LUMIPULSE G600II, which is a chemiluminescent enzyme immunoassay analyzer from Fujirebio. It detects disease markers of many types, including the hepatitis B core-related antigen (HBcrAg), the Alzheimer’s disease biomarkers β-amyloid(1-42), phospho-tau(181P) and total tau, and the cardiac marker Troponin-I (cTnI). We acquired it to address analytical needs in studies of HBV infections and Alzheimer’s disease.

These instruments join our 2016 acquisition, the KRYPTOR compact PLUS from B.R.A.H.M.S. Instruments/ThermoFisher Scientific, which also measures important biomarkers in cardiovascular disease (e.g., copeptin proAVP, MR-proANP and MR-proADM) and cancer, in our program to cover the full range of key parameters for patient evaluations.

All three instruments will work well alongside our well-established analytical powerhouses the ROCHE Cobas^®, the Stago STA Compact, the Perkin Elmer Wizard, the Meso Scale Diagnostics^® Sector imager and various Tecan readers.

To get the full picture of our analytical services, please visit our website and feel free to contact us directly with any specific questions.